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Table 1. Serum 25 (OH) D2+D3 Level in ng/ml
0 - < 12 month
Post-Tx
12 month
Post-Tx
24 month
Post-Tx
36 month
Post-Tx
(n562) (n536) (n539) (n516)
Severe Def. (<10) 0 0 0 0
Moderate Def. (10-20) 16 (25.8%) 6 (16.6%) 4 (10.3%) 3 (18.8%)
Mild Deficiency (21-30) 22 (35.4%) 7 (19.4%) 10 (25.6%) 3 (18.8%)
Sufficient Level (>30) 24 (38.7%) 23 (63.8%) 25 (64.1%) 10 (62.5%)
Tx, Transplant; Def., Deficiency.
S274 Poster Session Iinitiated pre-transplant in one patient, and 21 days to greater than
2 years in six patients (median of 61days).
We analyzed 7 patients with CMV viremia who were treated un-
der emergency IND because of lack of other reasonable therapeutic
options. All 7 patients had failed conventional antiviral therapy: all
patients had received ganciclovir and/or valganciclovir, 6 had re-
ceived foscarnet, and 4 had received CMV IG. The doses of
CMX001 in these patients ranged from 80 mg to 300 mg (approxi-
mately 2 to 4mg/kg); follow-up data was available for at least 4 weeks
in all patients. Virologic response was defined as more than a 90%
reduction (1 log 10) in viral load (VL) and complete response was de-
fined as an undetectable viral load.
The4males and3 females treatedhad amedianage of 55 years (range
11 to 69 years); theywere treatedwithCMX001 for amedian of 88 days
(range 29-131 days). The median reduction in VL was greater than 1.2
log 10 at 4 weeks. A complete response was observed in 3/5 (60%) pa-
tients who did not have mutations in the CMV polymerase UL54
gene; 2/5 had an average reduction in CMV by PCR of 1.2 log 10.
Neither of two patients with a relevant mutation in UL54 (L501F and
A987G) had a 1 log reduction in viremia at the last time point.
Two patients had pre-existing renal insufficiency; no dose adjust-
ment was needed based on kidney function. Four of 7 patients had
GVHD during treatment with CMX001. One patient experienced
C. difficile colitis, one experienced pancytopenia, one with a seizure
disorder experienced seizure, and one experienced severe GVHD.
No trends were observed in SAEs.
This case series demonstrates that CMX001 is a promising thera-
peutic option for the treatment of CMV disease in stem cell trans-
plant patients.
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A PROGNOSTIC INDEX THAT PREDICTS SURVIVAL OF MECHANICALLY
VENTILATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
RECIPIENTS
Solh, M., Oom, S., Isaksson Vogel, R., Shanley, R., Burns, L.J. University
of Minnesota, Minneapolis, MN
Purpose: The overall outcome of hematopoietic cell transplant re-
cipients (HCT) who requiremechanical ventilation (MV) has histor-
ically been poor. However, more recent studies have shown
improved survival. We evaluated the outcome of ventilated adult
HCT recipients at the University of Minnesota and sought a prog-
nostic index to predict 100 day post-MV overall survival (OS) based
on factors present at the time of MV.
Patients andMethods: A retrospective study of patients$ 18 years
of age (n5 1557) who received HCT at the University of Minnesota
between 1998 and 2009. Patients’ demographics and clinical out-
comes were prospectively collected from the transplant database.
Data regarding MV, organ failure and organ failure support were
retrospectively collected from patients’ records. 234 patients (15%)
required MV in the first 100 days post HCT and were divided into
a training set (n156) and a validation set (n 5 78). Multivariate
Cox regression and recursive partitioning were used to build a model
that classified patients into either good (class A) or poor (class B)
prognostic groups. The final model was assessed in the validation set.
Results: MV occurred prior to neutrophil engraftment (ANC $
500/ml x2 days) in 94 patients (40%). 137 patients (59%) were venti-
lated within 30 days of HCT.The 100 day post-MVOSwas 18% for
the total population. Karnofsky score, serum total bilirubin and cre-
atinine levels at time of MV, platelet count and acute GVHD were
predictors of worse OS in the training set. Recursive partitioning
on the training set showed that creatinine\ 2 mg/dl, platelet count
. 20,000/ml and total bilirubin\ 5 mg/dl at time of MV predicted
a good prognostic group (class A) with 38% OS in the training set,
35% in the validation set and 37% in the total population.In con-
trast, the poor prognostic group (class B), had 9% 100 day OS in
the training set, 7% in the validation set and 8% in the total
population. Class A patients were less likely to develop kidney failure
(34% versus 70%, p\ 0.0001), require dialysis (25% versus 41%,
p 5 0.0202) and less likely to develop liver failure (5% versus
38%, p\ 0.0001) during MV.
Conclusion: MV support is justified in HCT recipients with good
prognostic features that are easily identified at the time of ventilation
need. Conversely, initiation of MV is questionable for patients with
poor prognostic features. For more universal use, this prognostic index
requires validation at other centers and in other patient populations.332
VITAMIN D DEFICIENCY IN CHILDREN UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Desai, S.R.1, Tewari, P.1, Whelan, M.2, Kurtzberg, J.1, Prasad, V.K.1
1Duke University Medical Center, Durham, NC; 2Duke University
Medical Center, Durham, NC
Background:Hematopoietic stem cell transplantation (HSCT)may
increase the risk of Vitamin D deficiency from chemotherapy, radi-
ation, nutritional difficulties, graft versus host disease (GVHD), re-
stricted physical activity and limited sun exposure. Therefore,
defining the extent of this problem is clinically relevant and may
be therapeutically useful.
Methods: HSCT recipients, who were # 18 years of age, trans-
planted at Duke between 01/2007 and 03/2009 and had serum Vita-
min D measured, were included in this retrospective study. Total
numbers of subjects satisfying these criteria were 71 (24 female; 25
non-Caucasian). Diagnoses were malignant in 39 and nonmalignant
in 32 patients. Vitamin D status was defined by serum 25(OH)
D2+D3 levels as follows: severe deficiency,\10ng/ml; moderate de-
ficiency, 10-20ng/ml, mild deficiency, 21-30 ng/ml. Osteopenia was
recorded from X-rays that were performed for any clinical reason
during the study period.
Results: The median (range) age at HSCT was 6.7 years (0.1-18),
weight was 29.1 kg (4-86.4), height was 117.2 cm (54-181), and
post-transplant follow-up duration was 25.3 months (2.6-44.7). At
transplant, 22.5% and 42%of all subjects were below 25th percentile
for weight and height, respectively. Of 71 patients, 61 received mye-
loablative conditioning. Their median in-patient stay was 48 days
(25-140). All subjects had received TPN and the median duration
of TPN therapy was 64 days (range, 16-598). Overall, 46% of sub-
jects had vitamin D deficiency during the study period (details in ta-
ble). Vitamin D deficiency was present in 18 of 24 (75%) subjects
with prolonged diarrhea, in 7 of 11 (64%) subjects on pancreatic en-
zyme therapy, in 13 of 27 (48%) subjects with chronicGVHD, and in21 of 38 (55%) subjects with serum albumin\2.5 gm/dL. Osteope-
nia was seen in 32 (45%) subjects, half of whom had Vitamin D de-
ficiency.
Conclusions:Vitamin D deficiency is prevalent in pediatric patients
undergoing HSCT. Serum levels should be checked prospectively
before and after transplantation, treatment should be administered
for low levels and the clinical impact should be further studied.333
INCIDENCE AND RESPONSE TO TREATMENT OF ADENOVIRUS (ADV) IN-
FECTION WITH CIDOFAVIR (C) IN PEDIATRIC PATIENTS AFTER ALLOGE-
NEIC HCT
Morris, C.L.,Morris, J.D. Loma Linda University Hospital, Loma Linda,
CA; , NC; , CA
ADV infection occurs frequently and has a high mortality after
HCT. The antiviral cidofavir has activity against ADV, but has sig-
nificant renal and marrow toxicity. We report our centers incidence
of ADV and its association with type of transplant and GVHD (clin-
ically significant requiring . 1mg/kg solumedrol for at least 2
weeks). Between August 2002 and June 2010 76 patients received
Table 1. Post-AHSCT Patient Toxicities
Patients with
ONJ (N510)
Control Group
(N540) p-value
Febrile days
Mean (Std dev) 2.20 (3.12) 3.30 (3.83) 0.524
Range 0-9 0-15
Lenght of hospital stay in days
Mean (Std dev) 18.20 (7.76) 18.58 (8.44) 0.541
Range 13-38 11-59
Days to ANC engraftment
Mean (Std dev) 10.30 (0.95) 10.58 (1.13) 0.482
Range 9-12 9-15
Days to platelet engraftment
Mean (Std dev) 12.20 (1.62) 12.48 (2.91) 0.776
Range 10-15 10-24
Nausea/Vomiting
Grade 0 (%) 1 (10) 2 (5) 0.753
Grade 1 (%) 3 (30) 21 (52.5)
Grade 2 (%) 6 (60) 15 (37.5)
Grade 3 (%) 0 (0) 2 (5)
Mucositis
Grade 0 (%) 4 (40) 13 (35.5) 0.889
Grade 1 (%) 2 (20) 12 (30)
Grade 2 (%) 3 (30) 11 (27.5)
Grade 3 (%) 1 (10) 4 (10)
Diarrhea
Grade 0 (%) 0 (0) 4 (10) 0.261
Grade 1 (%) 1 (10) 9 (22.5)
Grade 2 (%) 4 (40) 11 (27.5)
Grade 3 (%) 5 (50) 15 (37.5)
Poster Session I S275allogeneicHCT’s. ADV infection was documented in 19 (25%). The
initial site of infection wasGI in 18 andGU in 1. Initial findings were
stool pcr or culture of stool or GI biopsy simultaneous with viremia
in 1. Plasma pcr’s were performed in 11 cases and viremia was found
0-11 days after GI detection in 10. This delay may reflect the way
monitoring was performed rather than any characteristic of ADV in-
fection. All patients except 2 received treatment with CDV 1mg/kg
3x per week. There were 4 cases in 34 patients receiving grafts
from family donors (12%). The incidence in patients receiving
HCT from unrelated donors was 3 fold greater 15/42 (36%). In
both groups 3/4 of ADV infections were preceded by clinically signif-
icant GVHD (3 of 4 sibling HCT and 11 of 15 unrelated HCT).
Since GVHD occurs more commonly after unrelated HCT we
looked at incidence of ADV infection using GVHD and transplant
type as risk factors. 22 of 42 (52%) recipients of unrelated HCT de-
veloped GVHD and 11 ADV infections (50%) occurred in these pa-
tients. Among recipients of relatedHCT 11 of 34 developedGVHD
and 3 of these ADV infection (27%) compared to1 of 23 (4%) devel-
oping ADV without prior GVHD. Most cases developing ADV in-
fection after GVHD had a typical time course, occurring 30-80
days after HCT and 1-8 weeks of steroid therapy. In contrast, 5 cases
occurring without GVHD occurred in patients with congenital im-
mune deficiency or after 2cd and 3rdHCT’s for relapse. Survival was
80% (4 of 5) in patients with ADV infection occurring before or in
absence of GVHD (median 2yr). For patients with GVHD and
ADV infection treatment success was 3 of 11 for unrelated HCT
and 3 of 4 for related HCT. Most deaths were due to combination
of toxicity and GVHD usually after control of ADV infection with
C. ADV infection after HCT correlates closely with GVHD and
unrelated donor graft. Treatment success depends both treatment
of associated GVHD and organ toxicity as it does supression of
ADV.Grade 4 (%) 0 (0) 1 (2.5)
Bacteremia
Yes (%) 3 (30) 12 (30) 1.000
Mean (Std dev) were examined by Student T-test. Frequency (%) were
examined by Mantel-Haenszel Chi-Square.334
ORAL AND SYSTEMIC COMPLICATIONS OF MYELOMA PATIENTS WITH
BISPHOSPHONATE-INDUCED OSTEONECROSIS OF THE JAW: A CASE-
CONTROL STUDY
Toro, J.J.1,2, Varadarajan, P.2, Schneider, D.L.1, Lee, S.1, Chao, J.-H.1,
Frye, B.L.1, Neumon, B.1, Haile, D.J.1, Freytes, C.O.1,2 1South Texas
Veterans Health Care System, San Antonio, TX; 2University of Texas
Health Science Center at San Antonio, San Antonio, TX
Background: The incidence of bisphosphonate-induced osteonec-
rosis of the jaw (BONJ) in patients with multiple myeloma (MM)
is estimated to be between 5-15%. It is unknown if BONJ canworsen
mucositis or impair its healing. Another concern is that necrotic
bone can harbor bacteria or other microorganisms that can cause
bacteremia and infection during prolonged periods ofmyelosuppres-
sion resulting in more severe toxicity after autologous stem cell
transplantation (AHSCT). The purpose of this study was to deter-
mine if transplant-associated toxicities in patients with BONJ was
different from patients without BONJ.
Patients andMethods:Using a retrospective case-control study de-
sign, 10 MM patients that met diagnostic criteria for BONJ prior to
AHSCT at our institution, between June 2005 and June 2010, were
matched to 40 MM patients without BONJ from our program’s da-
tabase. Patients were matched based on age, stage, gender, ethnicity,
performance status and conditioning regimen prior to AHSCT.
Pre-transplant factors analyzed included: smoking, type of bi-
sphosphonate received and number of infusions, dental extractions
1-year pretransplantation and total edentia. Posttransplant toxicities
analyzed included: mucositis, nausea/vomiting, diarrhea, bacter-
emia, febrile days, engraftment, and length of hospital stay.
Results: The incidence and severity of all toxicities analyzed were
similar in both groups including mucositis, bacteremia and febrile
days (see table). Engraftment and hospital stay were also similar.
Of interest, patients with history of smoking were associated with
a higher risk of BONJ (OR, 4.5; 95% CI, 1.05-19.25, p 5 0.043).
Despite the fact that patients who underwent dental extractions
within one year of AHSCT did not experience a higher risk of
BONJ, total edentia was associated with a significant increase of
BONJ risk (OR, 8.5; 95% CI, 1.83-9.42, p 5 0.006). Type of bi-
sphosphonate and number of infusions received did not increase
the risk of BONJ in our study.Conclusions: Oral and systemic posttransplant complications of
patients with BONJ were similar to patients without BONJ in this
case-control study. The outcome of this study suggests that AHSCT
can be performed safely in patients with BONJ. In our analysis,
patients who smoked and edentulous patients were at higher risk
of developing BONJ.335
EMPRIRICAL ANTIFUNGAL THERAPY OF PERSISTENT NEUTROPENIC FE-
VER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION WITH CASPOFUNGIN OR LIPOSOMAL AMPHOTERICIN B
Sanz, J., Pellicer, D., Montesinos, P., Martinez, D., Salavert, M.,
Lorenzo, I., Palau, J., Martın, G., Jarque, I., de la Rubia, J.,
Moscardo, F., Martinez, J., Sanz, G., Sanz, M.A. Hospital Universitario
La Fe, Valencia, Spain
Caspofungin and liposomal amphotericin B (L-ampho B) have
shown similar efficacy for the treatment of persistent febrile neutro-
penia (PFN). Although patients undergoing allogeneic stem cell
transplantation (allo-SCT) are at high risk of life-threatening inva-
sive fungal infections (IFI), specific data on the best choice of anti-
fungal agent in this setting are scarce.
The aim of the present study was to analyse the efficacy of caspo-
fungin and L-ampho B used as empirical treatment of PFN in two
consecutive historical cohorts of patients undergoing allo-SCT at
a single institution. Efficacy was evaluated using a five-part compos-
ite end point.
From 2000 to 2009, we analyzed 134 consecutive patients under-
going allo-SCT who received empirical antifungal therapy for the
treatment of PFN: a first cohort of 61 patients treated with L-ampho
B (2000-2004) vs a second cohort of 73 patients treated with caspo-
fungin (2005-2009). Most baseline characteristics were comparable
between both groups. However, patients in the caspofungin group
received more unrelated donor cord blood transplants (63% vs
41%, p 5 0.011).
